JANONE INC (JAN) Fundamental Analysis & Valuation

NASDAQ:JAN • US47089W1045

2.23 USD
+0.09 (+4.21%)
Last: Jul 12, 2024, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This JAN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

0

Overall JAN gets a fundamental rating of 0 out of 10. We evaluated JAN against 193 industry peers in the Pharmaceuticals industry. JAN has a bad profitability rating. Also its financial health evaluation is rather negative. JAN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. JAN Profitability Analysis

1.1 Basic Checks

  • JAN had negative earnings in the past year.
  • JAN had a negative operating cash flow in the past year.
  • JAN had negative earnings in 4 of the past 5 years.
  • JAN had negative operating cash flow in 4 of the past 5 years.
JAN Yearly Net Income VS EBIT VS OCF VS FCFJAN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M -10M -15M

1.2 Ratios

  • With a Return On Assets value of -107.89%, JAN is not doing good in the industry: 83.08% of the companies in the same industry are doing better.
  • JAN's Return On Equity of -262.72% is on the low side compared to the rest of the industry. JAN is outperformed by 76.92% of its industry peers.
Industry RankSector Rank
ROA -107.89%
ROE -262.72%
ROIC N/A
ROA(3y)-43.38%
ROA(5y)-41.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JAN Yearly ROA, ROE, ROICJAN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200 -300

1.3 Margins

  • JAN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JAN Yearly Profit, Operating, Gross MarginsJAN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. JAN Health Analysis

2.1 Basic Checks

  • JAN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • JAN has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, JAN has a worse debt to assets ratio.
JAN Yearly Shares OutstandingJAN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
JAN Yearly Total Debt VS Total AssetsJAN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -3.96, we must say that JAN is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of JAN (-3.96) is worse than 60.00% of its industry peers.
  • JAN has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.14, JAN is in line with its industry, outperforming 46.15% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -3.96
ROIC/WACCN/A
WACC9.51%
JAN Yearly LT Debt VS Equity VS FCFJAN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M 20M

2.3 Liquidity

  • JAN has a Current Ratio of 0.15. This is a bad value and indicates that JAN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.15, JAN is doing worse than 98.46% of the companies in the same industry.
  • JAN has a Quick Ratio of 0.15. This is a bad value and indicates that JAN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • JAN has a Quick ratio of 0.15. This is amonst the worse of the industry: JAN underperforms 97.95% of its industry peers.
Industry RankSector Rank
Current Ratio 0.15
Quick Ratio 0.15
JAN Yearly Current Assets VS Current LiabilitesJAN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. JAN Growth Analysis

3.1 Past

  • JAN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -163.18%.
  • The Revenue for JAN has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-163.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-110.79%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JAN Yearly Revenue VS EstimatesJAN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

Find the best growth stocksShow best growing peers

0

4. JAN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for JAN. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JAN Price Earnings VS Forward Price EarningsJAN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JAN Per share dataJAN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. JAN Dividend Analysis

5.1 Amount

  • JAN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

JAN Fundamentals: All Metrics, Ratios and Statistics

JANONE INC

NASDAQ:JAN (7/12/2024, 8:00:02 PM)

2.23

+0.09 (+4.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-22
Earnings (Next)08-15
Inst Owners5.8%
Inst Owner Change17.07%
Ins Owners1.88%
Ins Owner Change0%
Market Cap26.02M
Revenue(TTM)N/A
Net Income(TTM)-20.04M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.41
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.97
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS0
BVpS0.65
TBVpS-0.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -107.89%
ROE -262.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.38%
ROA(5y)-41.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.15
Quick Ratio 0.15
Altman-Z -3.96
F-Score1
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-163.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-110.79%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y65.58%
FCF growth 3YN/A
FCF growth 5Y-17.16%
OCF growth 1Y47.72%
OCF growth 3YN/A
OCF growth 5Y-18.82%

JANONE INC / JAN FAQ

Can you provide the ChartMill fundamental rating for JANONE INC?

ChartMill assigns a fundamental rating of 0 / 10 to JAN.


What is the valuation status for JAN stock?

ChartMill assigns a valuation rating of 0 / 10 to JANONE INC (JAN). This can be considered as Overvalued.


How profitable is JANONE INC (JAN) stock?

JANONE INC (JAN) has a profitability rating of 0 / 10.


How financially healthy is JANONE INC?

The financial health rating of JANONE INC (JAN) is 1 / 10.